July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Michael Serzan: Kidney Clinical Science Symposium at ASCO25
Jun 1, 2025, 11:25

Michael Serzan: Kidney Clinical Science Symposium at ASCO25

Michael Serzan, Genitourinary Medical Oncologist at Dana Farber Cancer Institute, shared a post on X:

“Kidney Clinical Science Symposium ASCO25

Abs4511: Dr David Braun presenting analysis of circulating blood and tumor microenvironment for response to Cabo/Nivo on CheckMate9ER.

Clinical implications:

  •  Cabo/Nivo responses enriched in TME with high VICM anti-tumor macrophage), high PD-L1, high plasma, and low circulating Treg

Further Reading

Biomarker-informed care for patients with renal cell carcinoma by Mackenzie McKinnon and Scott Haake

n = 150 (23% of ITT)

  •  PD-L1 staining
  •  4 PBMC markers
  •  4 ECM markers
  •  7 HnE HIF features.

ECM marker VICM (fragment of vimentin measures macrophage activity and immune status) was prognostic across both therapies.
Log regression models that integrated highly informatic features had AUCs of 0.76 for NIVO+CABO model and 0.72 for the SUN model.

NIVO+CABO arm determinants of response

  • high VICM (anti-tumor macrophage polarization)
  • high PD-L1
  • high plasma cell
  • high cancer cell  at the epithelial stromal interface
  • low circulating (Pro-C6)
  • low % circulating Treg (Foxp3+ CD4+)”

Michael Serzan: Kidney Clinical Science Symposium at ASCO25

More posts featuring Michael Serzan.